Replies to post #195232 on Biotech Values

[DewDiligence]

SNY, LLY settle litigation wrt LLY’s Lantus FoB, called Basaglar:

http://finance.yahoo.com/news/lilly-sanofi-reach-settlement-agreement-133300869.html

Eli Lilly and Company has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.

As a part of the agreement, Lilly and its alliance partner, Boehringer Ingelheim, will have the ability to launch Basaglar in the U.S. on December 15, 2016. Under the terms of the agreement, Sanofi has granted Lilly a royalty-bearing license so Lilly can manufacture and sell Basaglar in the Kwikpen device globally. Further details regarding the settlement are confidential.

[DewDiligence]

Announced FoB Collaborations

[PFE returns Rituxan/Herceptin rights to Celltrion; PFE’s internal
(i.e. non-HSP) programs for these FoBs are more advanced than
the Celltrion programs originally partnered with HSP.]


Items are shown in reverse chronological order. This table does not purport to be exhaustive.

 
                     Date   Targets   Geography     iHub References 
 AZN-Fujifilm/Kyowa  7/15   Avastin   global        #msg-115666552 
 PFE(HSP)-PFNX       2/15   Lucentis  global        #msg-110725481 
 Merck KGaA-Hanwha   2/15   Enbrel    ex-US         #msg-110668714 
 EPRS-Livzon         9/14   5 mAbs    China         #msg-106600322 
 NeuClone-Serum Inst 7/14   10 mAbs   global        #msg-104136710 
 Liomont-Oncobiolgcs 6/14   2 mAbs    Mexico        #msg-103754486 
 PlantForm-PhrmaPrxs 6/14   Avastin   Brazil        #msg-103576633 
 Lupin-Yoshindo      4/14   Enbrel    Japan         #msg-101018361 
 EPRS-Ranbaxy        1/14   Remicade  Asia/Africa   #msg-95745192 
 BXLT-CHRS           9/13   Enbrel    ex-US         #msg-91645674 
 Oncobiolgcs-Huahai  5/13   #         global        #msg-87734336,#msg-87744882 
 Strides-Pfenex      4/13   Betaseron global        #msg-87014470 
 MRK-Samsng/BIIB     2/13   @         @             #msg-114478003,#msg-84781042,#msg-69629103 
 Catalent-UMN       12/12   various   Asia          #msg-82556713 
 Merck KGaA-RDY      6/12   oncology  global        #msg-76359649 
 Daiichi-CHRS        5/12   Enbrel    Asia          #msg-75397629 
 Fujifilm-Kyowa      3/12   Humira    unspecified   #msg-73800486 
 AGN-Bioton          2/12   insulin   US & Europe   #msg-74987123 
 AGN-AMGN           12/11   †         global        #msg-70097496,#msg-117190738 
 BXLT-MNTA          12/11   Humira    global        #msg-110925786 
 PFE(HSP)-Celltrion 10/09   z         global        #msg-84519981 
 MYL-Biocon          6/09   x         global        #msg-72421544,#msg-84561737 
 Procognia-UTR       n/a    Humira    unspecified   #msg-84340976 

†Herceptin, Avastin, Rituxan, Erbitux; AMGN working independently on Humira and Remicade.

@ Enbrel [worldwide except US/EU/Japan], Remicade [worldwide except EU/Russia/Turkey], Humira [worldwide except EU/Russia/Turkey], Herceptin [worldwide], Lantus [worldwide].

#Humira, Rituxan, Avastin, Herceptin.

x Nine products: Herceptin, Neulasta, Avastin, Humira, Enbrel, Lantus, Novolog, Humalog, one undisclosed.

z Remicade (approved in EU), Enbrel, Erbitux, Synagis, Humira, Avastin; Riruxan and Herceptin returned to Celltrion in 9/15.